Novartis Reports Tumours After $2.1m Gene Therapy

Novartis has received reports of nine tumour cases in children worldwide who received Zolgensma, its gene therapy for spinal muscular atrophy, since the treatment first gained authorisation in 2019. In two cases, researchers detected genetic material from the therapy’s delivery vehicle in the children’s DNA. Both children received treatment and remain under medical supervision.

The reports have put a high-priced treatment and its risks under scrutiny. Novartis said more than 6,000 patients worldwide have received Zolgensma through clinical trials, special access programmes and routine treatment. The company says it keeps reviewing new safety information and reported cases. Families and clinicians now await further details from regulatory authorities, but the information available about the children remains limited.

What the reports show

The British patient organisation SMA UK said on its website that researchers examined three of the nine children’s tumours in more detail. They detected vector DNA integration in two cases. In the third, the findings appeared to show no link between treatment and the tumour.

Those findings distinguish the cases, but don't settle the question. The reports don't establish that Zolgensma caused every tumour, and the available information provides no further details about the children. Novartis said the potential risk of tumour formation from vector DNA integration into the genome already appears in the product information.

That is the company’s stated safety position. It isn't a substitute for further information expected from regulatory authorities, and the source doesn't say when those authorities will report. For now, the public account consists of a small set of examined cases alongside a much larger total of patients who have received the treatment.

A breakthrough with a price tag

Zolgensma treats spinal muscular atrophy, a rare genetic disorder in which nerve cells die and muscles grow progressively weaker. Given as a single infusion to children under two, the treatment delivers a functional copy of the defective gene into cells and targets the cause of the disease.

Doctors hailed the treatment as a medical breakthrough in 2019. When it launched, it cost around $2.1 million, or CHF1.7 million, per treatment, depending on the country and region, and ranked as the world’s most expensive medicine at the time. The figures put the extraordinary price beside the safety questions now under examination: one treatment, a vast cost, and reports of tumours in children who received it.

The source doesn't explain how the price was set, how costs were distributed, or what access arrangements applied in particular countries. It does say patients received Zolgensma through clinical trials, special access programmes and routine treatment. Those routes brought a medicine presented as a breakthrough to more than 6,000 patients worldwide.

What remains unanswered

Novartis continues to review the safety information and says the potential risk appears in the product information. The two children whose cases showed vector DNA integration have received treatment and remain under medical supervision. The reports leave key details limited, though, and families await further information from regulatory authorities.

The available facts show the treatment’s reach and the limits of what has been disclosed about these cases. They don't establish a connection in all nine children, and one of the three tumours examined in more detail appeared unrelated to treatment. Nor do they resolve what the two cases of detected vector DNA integration mean. For families weighing treatment, unanswered questions remain alongside the company’s safety review and a price once described as the highest for any medicine.